StockNews.AI
LIVN
StockNews.AI
104 days

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

1. LivaNova reported $316.9 million Q1 revenue, up 7.4% year-on-year. 2. However, diluted loss per share was $6.01, affecting investor confidence.

2m saved
Insight
Article

FAQ

Why Bearish?

The significant loss per share of $6.01 may concern investors, overshadowing revenue growth.

How important is it?

The revenue growth is positive, but the loss per share may detract from overall investor sentiment.

Why Short Term?

Immediate investor reactions are likely due to recent financial losses, affecting stock performance soon.

Related Companies

MDTSYKZBH
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance. Financial Summary and Highlights(1) First-quarter revenue of $316.9 million increased 7.4% on a reported basis, 8.9% on a constant-currency basis, and 10.4% on an organic basis as compared to the prior-year period First-quarter U.S. GAAP diluted loss per share of $6.01, impacted by recording SNIA.

Related News